Pogostone
(Synonyms: 广藿香酮) 目录号 : GC45550
A pyranone with antifungal and insecticidal activities
Cas No.:23800-56-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Pogostone is a pyranone that has been found in the essential oil of P. cablin, also known as patchouli oil, and has antifungal and insecticidal activities.1 It is active against a laboratory strain and clinical isolates of C. albicans (MICs = 49 and 12-97 μg/ml, respectively). It reduces fungal load in the vagina in a mouse model of fluconazole-resistant vulvovaginal candidiasis when administered at topical doses of 1, 2, and 4 mg/kg per day or oral doses of 20, 40, and 80 mg/kg per day.2 Pogostone is toxic to S. exigua and S. litura larvae with LC50 values of 545.61 and 986.88 mg/L for dietary administration and 519.48 and 1,041.42 mg/L for contact application.3 It also has antifeedant activity against third instar larvae against S. exigua and S. litura.
References
1. Yi, Y.-Y., He, J.-J., Su, J.-Q., et al. Synthesis and antimicrobial evaluation of pogostone and its analogues. Fitoterapia 84, 135-139 (2013).
2. Li, Y.-C., Liang, H.-C., Chen, H.-M., et al. Anti-Candida albicans activity and pharmacokinetics of pogostone isolated from Pogostemonis Herba. Phytomedicine 20(1), 77-83 (2012).
3. Huang, S.-H., Xian, J.-D., Kong, S.-Z., et al. Insecticidal activity of pogostone against Spodoptera litura and Spodoptera exigua (Lepidoptera: Noctuidae). Pest Manag. Sci. 70(3), 510-516 (2014).
| Cas No. | 23800-56-8 | SDF | |
| 别名 | 广藿香酮 | ||
| Canonical SMILES | CC(C)CCC(C1=C(O)C=C(C)OC1=O)=O | ||
| 分子式 | C12H16O4 | 分子量 | 224.3 |
| 溶解度 | DMF: 1.6mg/mL,DMSO: 3mg/mL,Ethanol: 3mg/mL,Ethanol:PBS (pH 7.2) (1:5): 0.16mg/mL | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.4583 mL | 22.2916 mL | 44.5831 mL |
| 5 mM | 0.8917 mL | 4.4583 mL | 8.9166 mL |
| 10 mM | 0.4458 mL | 2.2292 mL | 4.4583 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Photo-protective activity of Pogostone against UV-induced skin premature aging in mice
Exp Gerontol 2016 May;77:76-86.PMID:26929999DOI:10.1016/j.exger.2016.02.017.
Pogostone, a chemical constituent of patchouli oil, has been confirmed to possess favorable anti-inflammatory property. In the present study, we investigated the possible anti-photoaging potential of Pogostone and the underlying mechanism against UV-induced skin damage in mice. The macroscopic and histopathological lesions were significantly ameliorated by pretreatment of Pogostone as compared to the VC group. Furthermore, topical application of Pogostone markedly increased the activities of the antioxidant enzymes, including catalase (CAT), superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px), and observably decreased malonaldehyde (MDA) level. Analysis of inflammatory cytokines showed obvious down-regulation of tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), interleukin-1β (IL-1β) and cyclooxygenase-2 (COX-2), prostaglandin E2 (PGE2) in the Pogostone groups. In addition, Pogostone pretreatment evidently inhibited the abnormal expression of matrix metalloproteinases (MMP-1 and MMP-3). Taken together, Pogostone exhibited prominent photo-protective activity mainly by its antioxidative and anti-inflammatory properties, promising it as an effective alternative pharmaceutical therapy for photoaging.
Pogostone inhibits the activity of CYP3A4, 2C9, and 2E1 in vitro
Pharm Biol 2021 Dec;59(1):532-536.PMID:33915070DOI:10.1080/13880209.2021.1917630.
Context: Pogostone possesses various pharmacological activities, which makes it widely used in the clinic. Its effect on the activity of cytochrome P450 enzymes (CYP450s) could guide its clinical combination. Objective: To investigate the effect of Pogostone on the activity of human CYP450s. Materials and methods: The effect of Pogostone on the activity of CYP450s was evaluated in human liver microsomes (HLMs) compared with blank HLMs (negative control) and specific inhibitors (positive control). The corresponding parameters were obtained with 0-100 μM Pogostone and various concentrations of substrates. Results: Pogostone was found to inhibit the activity of CYP3A4, 2C9, and 2E1 with the IC50 values of 11.41, 12.11, and 14.90 μM, respectively. The inhibition of CYP3A4 by Pogostone was revealed to be performed in a non-competitive and time-dependent manner with the Ki value of 5.69 μM and the KI/Kinact value of 5.86/0.056/(μM/min). For the inhibition of CYP2C9 and 2E1, Pogostone acted as a competitive inhibitor with the Ki value of 6.46 and 7.67 μM and was not affected by the incubation time. Discussion and conclusions: The inhibitory effect of Pogostone on the activity of CYP3A4, 2C9, and 2E1 has been disclosed in this study, implying the potential risk during the co-administration of Pogostone and drugs metabolized by these CYP450s. The study design provides a reference for further in vivo investigations to validate the potential interaction.
Pogostone Enhances the Antibacterial Activity of Colistin against MCR-1-Positive Bacteria by Inhibiting the Biological Function of MCR-1
Molecules 2022 Apr 28;27(9):2819.PMID:35566163DOI:10.3390/molecules27092819.
The emergence of the plasmid-mediated colistin resistance gene mcr-1 has resulted in the loss of available treatments for certain severe infections. Here we identified a potential inhibitor of MCR-1 for the treatment of infections caused by MCR-1-positive drug-resistant bacteria, especially MCR-1-positive carbapenem-resistant Enterobacteriaceae (CRE). A checkerboard minimum inhibitory concentration (MIC) test, a killing curve test, a growth curve test, bacterial live/dead assays, scanning electron microscope (SEM) analysis, cytotoxicity tests, molecular dynamics simulation analysis, and animal studies were used to confirm the in vivo/in vitro synergistic effects of Pogostone and colistin. The results showed that Pogostone could restore the bactericidal activity of colistin against all tested MCR-1-positive bacterial strains or MCR-1 mutant−positive bacterial strains (FIC < 0.5). Pogostone does not inhibit the expression of MCR-1. Rather, it inhibits the binding of MCR-1 to substrates by binding to amino acids in the active region of MCR-1, thus inhibiting the biological activity of MCR-1 and its mutants (such as MCR-3). An in vivo mouse systemic infection model, Pogostone in combination with colistin resulted in 80.0% (the survival rates after monotherapy with colistin or Pogostone alone were 33.3% and 40.0%) survival at 72 h after infection of MCR-1-positve Escherichia coli (E. coli) ZJ487 (blaNDM-1-carrying), and Pogostone in combination with colistin led to one or more order of magnitude decreases in the bacterial burdens in the liver, spleen and kidney compared with Pogostone or colistin alone. Our results confirm that Pogostone is a potential inhibitor of MCR-1 for use in combination with polymyxin for the treatment of severe infections caused by MCR-1-positive Enterobacteriaceae.
Pogostone attenuates adipose tissue inflammation by regulating the adipocyte-macrophage crosstalk via activating SIRT1
Food Funct 2022 Nov 14;13(22):11853-11864.PMID:36314728DOI:10.1039/d2fo01450e.
Adipose tissue inflammation is believed to be the most important contributor to obesity associated insulin resistance and related metabolic diseases. Pogostone (PO) is a major component of the essential oil from Pogostemon cablin (Blanco) Benth., which is used as a natural additive for food flavoring. Herein, we explored the therapeutic effects and the underlying mechanisms of PO against adipose tissue inflammation. In TNF-α-induced differentiated adipocytes, PO downregulated the phosphorylation of MAPKs and the NF-κB pathway by triggering the SIRT1 activation. In vitro, PO suppressed the migratory ability of macrophages to inflammatory adipocytes and reduced inflammatory cytokine and chemokine expression in macrophages stimulated by conditioned media from differentiated adipocytes. Notably, the above effects are attributed to blocking of the MAPK and NF-κB signal activation by hampering the SIRT1 expression, as pre-treatment with an inhibitor of SIRT1-Ex527 on adipocytes abolished the anti-inflammatory effects of PO. Furthermore, PO mitigated the levels and expressions of inflammatory cytokines in the serum and epididymal adipose tissue of LPS induced mice, as well as increased the level of the anti-inflammatory cytokine IL-10 and observably inhibited the cytokine and chemokine expression in adipose tissue. PO suppressed the phosphorylation of MAPK and NF-κB signals and promoted the SIRT1 expression in adipose tissue. In summary, our results demonstrate that PO ameliorates adipose tissue inflammation through activating SIRT1, which modulates the inflammatory pathway comprising MAPK and NF-κB signals and drives the beneficial reciprocal interactions between adipocytes and macrophages. Thus, our study suggests that PO may be a bioactive constituent for treatment of obesity and related metabolic diseases by targeting adipose tissue inflammation.
Pogostone induces autophagy and apoptosis involving PI3K/Akt/mTOR axis in human colorectal carcinoma HCT116 cells
J Ethnopharmacol 2017 Apr 18;202:20-27.PMID:27416805DOI:10.1016/j.jep.2016.07.028.
Ethnophamacological relevance: Pogostemon cablin is a medicinal herb widely used to treat gastrointestinal diseases in many Asian countries. Pogostone is an important constituent of Pogostemon cablin, and possesses various bioactivitys. In this study, we performed to investigate the anti-colorectal tumor property of Pogostone by inducing aurophagy and apoptosis in human colorectal cancer cells, and to define the potential molecular mechanisms. Materials and methods: In vitro, The anti-tumor activity of Pogostone was assessed using MTT assay. Autophagy was monitored by transmission electron microscopy observation and mRFP-GFP-LC3 fluorescence analysis in colorectal tumor cell line. Apoptosis was measured by flow cytometry and annexinV-FITC/PI staining. The protein expressions or activition of LC3-Ⅱ, AKT, mTOR, caspase-3 and caspase-7 were detected through western blotting. In vivo, the anti-tumor effect of Pogostone was tested with HCT116 colorectal tumor cells transplantation tumor model. The expression of Ki-67 was determined by Immunohistochemistry staining and the apoptosis was evaluated using TUNEL assay. Results: In vitro, Pogostone exhibits significant anti-tumor activity against human cancer cell lines, especially for HCT116 (18.7±1.93μg/ml). Transmission electron microscopy observation, mRFP-GFP-LC3 fluorescence analysis, flow cytometry and assay and western blotting detection revealed that the anti-colorectal tumor activity of Pogostone was dependent on inducing autophagy and apoptosis through up-regulating the expression of LC3-Ⅱ, cleaved caspase-7 and caspase-3, and decreasing the phosphorylation of AKT/mTOR. In vivo, 150mg/kg Pogostone inhibited the HCT116 tumor growth in immunodeficient mice with an inhibitory rate of 43.3%, decreased the expression of Ki67, and induced apoptosis in three days. Conclusion: Pogostone showed anti-colorectal tumor effects by inducing autophagy and apoptosis involving PI3K/Akt/mTOR axis. Thus, Pogostone may be a promising lead compound to be further developed for cancer therapy.